Compare Amylx Pharmaceuticals Inc (AMLX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Valero Energy Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Valero Energy Corporation trades at $285.35 (market cap $83.35B). The key difference: Valero Energy Corporation is far larger — about 42.1× Amylx Pharmaceuticals Inc's market cap, and Valero Energy Corporation pays a 1.71% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | VLO | |
|---|---|---|
Market Cap | $1.98B | $83.35B |
Sector | Health | Energy |
52-Week High | $18.70 | $282.88 |
52-Week Low | $7.64 | $131.77 |
Enterprise Value | $1.70B | $89.10B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Valero Energy (VLO) trades at $280.69, down 0.2% on the day, with strong technical momentum as the stock approaches resistance near $285. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 expected at $10.03 EPS. Fundamentals show solid profitability with 17.72% ROE and improving cash flow projections for 2026. Recent news highlights strong refining margins and Gulf Coast operational advantages supporting the bullish outlook.
VLO presents a compelling investment case with strong earnings momentum and favorable industry dynamics, though investors face risks from energy market volatility and declining revenue trends. The stock trades above the consensus price target of $257.57, suggesting limited near-term upside despite 58% analyst buy ratings. The upcoming dividend payment of $1.20 provides additional shareholder return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
